You have 9 free searches left this month | for more free features.

NKG2D

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Advanced Sarcoma Trial (NKG2D-CAR memory T cell)

Not yet recruiting
  • Advanced Sarcoma
  • NKG2D-CAR memory T cell
  • (no location specified)
Oct 17, 2023

Ovarian Cancer Trial in Hangzhou (NKG2D CAR-NK)

Recruiting
  • Ovarian Cancer
  • NKG2D CAR-NK
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Mar 26, 2023

AML Trial in Hangzhou (NKG2D CAR-NK)

Recruiting
  • AML
  • NKG2D CAR-NK
  • Hangzhou, Zhejiang, China
  • +1 more
Feb 17, 2023

Gastric Cancer, Pancreatic Cancer, Solid Tumor Trial in Beijing (KD-496)

Not yet recruiting
  • Gastric Cancer
  • +2 more
  • KD-496
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Nov 15, 2023

Refractory Metastatic Colorectal Cancer Trial in Hangzhou (NKG2D CAR-NK)

Recruiting
  • Refractory Metastatic Colorectal Cancer
  • NKG2D CAR-NK
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University
Jan 16, 2022

Gastric Cancer, Pancreatic Cancer, Solid Tumor Trial in Beijing (KD-496)

Recruiting
  • Gastric Cancer
  • +2 more
  • KD-496
  • Beijing, China
    Chinese PLA General Hospital
Oct 13, 2022

Refractory Metastatic Colorectal Cancer Trial in Guangzhou (CAR-T infusion)

Recruiting
  • Refractory Metastatic Colorectal Cancer
  • CAR-T infusion
  • Guangzhou, Guangdong, China
    The Third Affiliated Hospital of Guangzhou Medical University
Feb 9, 2022

Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma Trial in Jiujiang (NKG2D-based CAR T-cells)

Recruiting
  • Hepatocellular Carcinoma
  • +3 more
  • NKG2D-based CAR T-cells
  • Jiujiang, Jiangxi, China
    Xunyang Changchun Shihua Hospital
Nov 20, 2021

Safety and Efficacy Trial in Sanhe (CAR-NK cells)

Recruiting
  • Safety and Efficacy
  • CAR-NK cells
  • Sanhe, Hebei, China
    Hebei Yanda Lu Daopei Hospital
Feb 9, 2022

CRC, Solid Tumor Trial in Beijing (KD-025)

Recruiting
  • CRC
  • Solid Tumor
  • KD-025
  • Beijing, Beijing, China
    Chinese PLA General Hospital
May 16, 2022

Advanced Solid Tumors Trial in Hangzhou (Universal Chimeric Natural Killer Receptor Modified T-cells (CNK-UT))

Recruiting
  • Advanced Solid Tumors
  • Universal Chimeric Natural Killer Receptor Modified T-cells (CNK-UT)
  • Hangzhou, China
    First affiliated hospital, School of Medicine, Zhejiang Universi
Aug 3, 2023

Advanced Solid Tumor Trial in Shanghai (IMC008)

Recruiting
  • Advanced Solid Tumor
  • Shanghai, Shanghai, China
    Shanghai Changhai Hospital
Apr 19, 2023

Acute Myeloid Leukemia Trial (NK cells, Talazoparib 1 MG [Talzenna])

Not yet recruiting
  • Acute Myeloid Leukemia
  • NK cells
  • Talazoparib 1 MG [Talzenna]
  • (no location specified)
Jan 9, 2023

Cancer, Malignancy, Refractory Cancer Trial in Singapore (Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted ?d T

Not yet recruiting
  • Cancer
  • +3 more
  • Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)
  • Singapore, Singapore
    National University Hospital
Mar 20, 2022

Recurrent Glioblastoma Trial (NKG2D CAR-T)

Not yet recruiting
  • Recurrent Glioblastoma
  • NKG2D CAR-T
  • (no location specified)
Jan 16, 2021

Acute Myeloid Leukemia Trial in Hangzhou (NKG2D CAR T-cells)

Not yet recruiting
  • Acute Myeloid Leukemia
  • NKG2D CAR T-cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital,College of Medicine, Zhejiang Univ
Dec 5, 2020

Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma Trial in Jiujiang (NKG2D-based CAR T-cells)

Withdrawn
  • Hepatocellular Carcinoma
  • +3 more
  • NKG2D-based CAR T-cells
  • Jiujiang, Jiangxi, China
    Affiliated hospital of jiujiang university
Oct 18, 2020

COVID-19 Trial in Chongqing (NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells)

Recruiting
  • COVID-19
  • NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells
  • Chongqing, China
    Chongqing Public Health Medical Center
Nov 16, 2020

Solid Tumor, Hepatocellular Carcinoma, Colorectal Cancer Trial in Nanjing (KD-025 CAR-T cells)

Not yet recruiting
  • Solid Tumor
  • +3 more
  • KD-025 CAR-T cells
  • Nanjing, Jiangsu, China
    The Affiliated Nanjing Drum Tower Hospital of Nanjing University
Sep 20, 2020

Unresectable Metastatic Colorectal Cancer Trial in Belgium, United States (CYAD-101, FOLFOX, FOLFIRI)

Recruiting
  • Unresectable Metastatic Colorectal Cancer
  • Tampa, Florida
  • +3 more
Nov 19, 2020

Colon Cancer Liver Metastasis Trial in Brussels (NKR-2 cells)

Unknown status
  • Colon Cancer Liver Metastasis
  • NKR-2 cells
  • Brussels, Belgium
    Institut Jules Bordet
Jun 18, 2020

Colon Cancer Liver Metastasis Trial in Brussels, Charleroi, Leuven (NKR-2 cells)

Unknown status
  • Colon Cancer Liver Metastasis
  • NKR-2 cells
  • Brussels, Belgium
  • +3 more
Jun 15, 2020

MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer Trial (S095029, Pembrolizumab 200 mg)

Not yet recruiting
  • MSI-H/dMMR Gastroesophageal-junction Cancer
  • MSI-H/dMMR Gastric Cancer
  • (no location specified)
Oct 30, 2023

SARS-CoV-2 (COVID-19) Infection, Advanced or Metastatic Hematological or Solid Tumor Trial in France (Autophagy inhibitor

Completed
  • SARS-CoV-2 (COVID-19) Infection
  • Advanced or Metastatic Hematological or Solid Tumor
  • Autophagy inhibitor (GNS651)
  • +3 more
  • Lyon, Rhône, France
  • +11 more
Sep 29, 2022

Relapsed/Refractory AML, AML, Adult, MDS Trial in United States (NKX101 - CAR NK cell therapy)

Recruiting
  • Relapsed/Refractory AML
  • +3 more
  • NKX101 - CAR NK cell therapy
  • Denver, Colorado
  • +6 more
Apr 8, 2022